 |
|
Current status of biosimilars in the treatment of inflammatory bowel diseases
Dong Il Park
Intest Res. 2016;14(1):15-20. Published online 2016 Jan 26 DOI: https://doi.org/10.5217/ir.2016.14.1.15
|
|
Citations to this article as recorded by
 Drugs with the highest drug expenditure in the Republic of Serbia
Boris Milijašević, Anđela Milak, Milan Ubavić, Dane Krtinić, Gorana Nedin-Ranković, Hristina Jovanović, Hristina Trajković, Dragana Milijašević, Radmila Popović, Nemanja Todorović, Mladena Lalić-Popović, Nikola Vukosav, Branko Baljak, Milan Tošić, Radmila
Hospital Pharmacology - International Multidisciplinary Journal.2023; 10(2): 1301. CrossRef International Coherence of Pediatric Drug Labeling for Drug Safety: Comparison of Approved Labels in Korea and the United States
Yun‐Kyoung Song, Nayoung Han, Gilbert J. Burckart, Jung Mi Oh
Clinical Pharmacology & Therapeutics.2020; 107(3): 530. CrossRef Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
Sang Hyoung Park, Jae Cheol Park, Milan Lukas, Martin Kolar, Edward V. Loftus
Intestinal Research.2020; 18(1): 34. CrossRef Characteristics of biological therapy in pediatric patients with Crohn’s disease
Andras Tarnok, Zoltan Kiss, Orsolya Kadenczki, Gabor Veres
Expert Opinion on Biological Therapy.2019; 19(3): 181. CrossRef Use of Biosimilars in Pediatric Inflammatory Bowel Disease
Lissy de Ridder, Amit Assa, Jiri Bronsky, Claudio Romano, Richard K. Russell, Nadeem A. Afzal, Almuthe C. Hauer, Daniela Knafelz, Paolo Lionetti, Caterina Strisciuglio, Gábor Veres, Harland Winter, Victorien M. Wolters, Malgorzata Sladek, Arnold G. Vulto,
Journal of Pediatric Gastroenterology and Nutrition.2019; 68(1): 144. CrossRef Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review
Laura Martelli, Laurent Peyrin-Biroulet
Current Medicinal Chemistry.2019; 26(2): 270. CrossRef Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
Tomoo Nakagawa, Taku Kobayashi, Kiyohiro Nishikawa, Fumika Yamada, Satoshi Asai, Yukinori Sameshima, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi
Intestinal Research.2019; 17(4): 504. CrossRef Knowledge and Viewpoints on Biosimilar Monoclonal Antibodies among Asian Physicians: Comparison with European Physicians
Soo-Kyung Park, Won Moon, Eun Soo Kim, Sang Hyun Park, Dong Il Park
The Korean Journal of Gastroenterology.2019; 74(6): 333. CrossRef The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC)
G.S. Fernandes, C. Sternberg, G. Lopes, R. Chammas, M.A.C. Gifoni, R.A. Gil, D.V. Araujo
Brazilian Journal of Medical and Biological Research.2018;[Epub] CrossRef Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
Vandana Midha, Ramit Mahajan, Varun Mehta, Vikram Narang, Arshdeep Singh, Kirandeep Kaur, Ajit Sood
Intestinal Research.2018; 16(1): 83. CrossRef Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence
Sean McConachie, Sheila M. Wilhelm, Pramodini B. Kale-Pradhan
Expert Review of Clinical Pharmacology.2017; 10(4): 391. CrossRef Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars
András Inotai, Christiaan P.J Prins, Marcell Csanádi, Dinko Vitezic, Catalin Codreanu, Zoltán Kaló
Expert Opinion on Biological Therapy.2017; 17(8): 915. CrossRef Anti-inflammatory and anti-apoptotic effects of rosuvastatin by regulation of oxidative stress in a dextran sulfate sodium-induced colitis model
Seung Kak Shin, Jae Hee Cho, Eui Joo Kim, Eun-Kyung Kim, Dong Kyun Park, Kwang An Kwon, Jun-Won Chung, Kyoung Oh Kim, Yoon Jae Kim
World Journal of Gastroenterology.2017; 23(25): 4559. CrossRef Advances in the use of biologics and other novel drugs for managing inflammatory bowel disease
Sang Hyoung Park, Satimai Aniwan, Edward V Loftus
Current Opinion in Pharmacology.2017; 37: 65. CrossRef Is Adsorptive Granulocyte and Monocyte Apheresis Effective as an Alternative Treatment Option in Patients with Ulcerative Colitis?
Seong Ran Jeon
Gut and Liver.2017; 11(2): 171. CrossRef
|